Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CERo Therapeutics Holdings ( (CERO) ) has provided an update.
On June 11, 2025, CERo Therapeutics Holdings, Inc. announced a reverse stock split at a 1-for-20 ratio, effective June 13, 2025, reducing outstanding shares from approximately 10,321,839 to 516,092. This move, approved by the board of directors, aims to adjust the company’s stock structure without altering the par value or authorized shares, and will affect equity incentive plans, preferred stock, and warrants proportionally. The reverse stock split is expected to impact trading on The Nasdaq Capital Market, with the company’s stock trading under the symbol ‘CERO’ and a new CUSIP number assigned.
The most recent analyst rating on (CERO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment. The company aims to integrate innate and adaptive immunity into a single therapeutic construct to optimize cancer therapy, with a proprietary approach that employs phagocytic mechanisms. CERo plans to initiate clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.
Average Trading Volume: 2,048,824
Technical Sentiment Signal: Sell
Current Market Cap: $2.84M
See more insights into CERO stock on TipRanks’ Stock Analysis page.